Life Extension Magazine February 2004
Cardiologists Overlook Lifesaving Discovery
By William Faloon
Impressive research published in 2003 indicates that coenzyme Q10 may have broader clinical applications than originally identified. These new human studies further validate the efficacy of coenzyme Q10 in the adjuvant treatment of cardiovascular disease.1-9
In particular, a study of heart attack patients showed that compared to placebo, supplementation with 120 mg a day of coenzyme Q10 reduced secondary cardiac events by 45% and significantly reduced the number of cardiac deaths. Many of these heart-attack patients were prescribed a “statin” drug to lower cholesterol levels. The major adverse effect of statin treatment was fatigue that occurred in 40.8% of the placebo group, whereas only 6.8% of the patients supplemented with coenzyme Q10 experienced fatigue.2
In newly published findings over the past year, positive results were shown when coenzyme Q10 was tested against disorders including macular degeneration, Parkinson’s disease, viral myocarditis, and hereditary neurodegenerative diseases.10-21 Additional studies indicate that coenzyme Q10 deficiency is linked with disorders such as infertility and brain atrophy.22-23
The Problem With “Statin” Drugs
Peter H. Langsjoen, MD, is the foremost authority on the use of coenzyme Q10 in the treatment of heart disease. His numerous research studies can be found in the world’s most prestigious scientific journals.24-32
In 1990, the Proceedings of the National Academy of Science published Dr. Langsjoen’s studies on the safety of statin drugs. Dr. Langsjoen explained that the mechanism by which statin drugs lower cholesterol also inhibits the natural biosynthesis of coenzyme Q10 in the liver. Dr. Langsjoen said that he conducted these studies because, “if lovastatin were to reduce levels of coenzyme Q10, this reduction would constitute a new risk of cardiac disease, since it is established that coenzyme Q10 is indispensable for cardiac function.” Dr. Langsjoen then reported that his animal and human studies showed that lovastatin does indeed lower levels of coenzyme Q10.30 Dr. Langsjoen went on to describe case histories of his lovastatin patients who suffered from progressive cardiac degeneration, but whose heart function improved after oral administration of coenzyme Q10.
Move forward to July 8, 2002, and we find that Dr. Langsjoen has become a vocal critic of statin drugs and has published a new paper titled “Statin-Induced Cardiomyopathy.” In an excerpt from this paper, Dr. Langsjoen describes his 17-year experience with statin drugs as follows:
“I have seen a frightening increase in heart failure secondary to statin usage, ‘statin cardiomyopathy.’ Over the past five years, statins have become more potent, are being prescribed in higher doses, and are being used with reckless abandon in the elderly and in patients with ‘normal’ cholesterol levels.”33
Dr. Langsjoen attributes these heart failure cases as being caused by “statin-induced coenzyme Q10 depletion” that is preventable if statin drug users supplemented with coenzyme Q10.
The “Forgotten” Merck Patents
The evidence supporting coenzyme Q10 as an antidote to statin drug complications is so clear that in 1989 and in 1990 Merck patented the use of coenzyme Q10 in combination with statin drugs to both prevent and treat these complications. However, Merck has neither exercised these patents nor educated physicians or patients about the necessity of taking coenzyme Q10 along with statin drugs. One of the two Merck patents states that:
“Since Coenzyme Q10…is of benefit in congestive heart failure patients, the combination with HMG-CoA reductase inhibitors (statin drugs) should be of value in such patients who also have the added risk of high cholesterol.”34
This patent was filed on behalf of Merck & Co on June 12, 1990. Now, almost 14 years later, most doctors and their patients remain ignorant that those taking statin drugs should also supplement with coenzyme Q10.
Last year, Life Extension made numerous calls to Merck’s press and media office to discuss its patent of the statin-coenzyme Q10 combination and why this invention was never brought to market. Unfortunately, we were unable to obtain a response as to why all of this time, money, and research had been undertaken by a leading pharmaceutical company only to let their patents sit in a file cabinet. To this day, few doctors are aware of the coenzyme Q10 depletion problem caused by statin drugs, despite the extensive research undertaken by Merck, Dr. Langsjoen, and others.
Dr. Julian Whitaker Files a Petition Against the FDA
Dr. Whitaker’s petitions state that statins deplete coenzyme Q10 stores in the body and increase congestive heart failure and cardiomyopathy risk. They call on the FDA commissioner to take immediate action to safeguard the millions of statin drug users.
Dr. Whitaker’s petition explains that statin drug use may be inducing adverse effects in as many as 575,000 people worldwide. The petitions go on to state that statin drugs work by blocking production of cholesterol and coenzyme Q10 in the same pathway, and that consumption of 100-200 mg per day of coenzyme Q10 can reverse depletion induced by statins.
Dr. Whitaker asserts that most patients and doctors do not realize that statin drugs block the production of coenzyme Q10. Dr. Whitaker went on to describe how coenzyme Q10 has been found to be essential for cellular energy production as well as for the functioning of the heart muscle. According to Dr. Whitaker:
“Statin drugs have proven in clinical trials to deplete coenzyme Q10, the ‘sparkplugs’ of the human body. Patients who take statin drugs without coenzyme Q10, particularly those with a history of heart disease, are especially prone to developing complications that can have fatal consequences.”35
FDA Fails to Protect Statin Users
The failure of the FDA to amend the drug package insert to recommend that statin users supplement with coenzyme Q10 is a medical travesty. Since the underlying science is irrefutable, this is a blatant example of large drug companies influencing the FDA into not taking actions that would save lives.
Our opinion as to why drug companies may not want this label change is that it could reduce sales of their statin drugs. After all, if doctors told patients that statin drugs could cause heart muscle degeneration, many cardiac patients would refuse to take this class of drug. There is also an economic issue. Those covered by health insurance often have their prescription drugs subsidized, while government programs provide low-income people with free drugs. If these patients were told they had to buy coenzyme Q10 supplements if they are prescribed a statin drug, many would not be willing or able to bear this extra cost.
On the flip side, more statin drugs could be sold if there were fewer side effects encountered, such as muscle pain, fatigue, liver toxicity, heart failure, etc. A lot of statin drug prescriptions are not refilled because of side effects, so drug companies may be shortchanging themselves in the long run by not recommending coenzyme Q10 supplementation.